Skip to main content
SpringerLink
Log in

Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science

  • Consensus Statement
  • Published:
Osteoporosis International Aims and scope Submit manuscript

An Erratum to this article was published on 04 September 2008

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. van Staa TP, Leufkens HGM, Abenhaim L, Begaud B, Zhang B, Cooper C (2000) Use of oral corticosteroids in the United Kingdom. Q Med J 93:105–111

    Google Scholar 

  2. Canalis E, Bilezekian JP, Angeli A, Giustina A (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34:593–598

    Article  PubMed  CAS  Google Scholar 

  3. van Staa TP, Leufkens HGM, Cooper C (2002) A meta-analysis of the epidemiology of corticosteroid-induced osteoporosis. Osteoporos Int 13:777–787

    Article  PubMed  Google Scholar 

  4. van staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol 39:1383–1389

    Article  Google Scholar 

  5. Van Staa T, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000

    Article  PubMed  Google Scholar 

  6. Laan RFJM, Van Riel PLCM, van de Putte LBA, van Erning LJTO, van’t Hof MA, Lemmens JAM (1993) Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid-arthritis - a randomized, controlled-study. Ann Intern Med 119:963–968

    PubMed  CAS  Google Scholar 

  7. Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893–899

    Article  PubMed  Google Scholar 

  8. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J (1990) Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. Am Rev Resp Dis 142:104–107

    PubMed  CAS  Google Scholar 

  9. van Staa TP, Laan RF, Barton IP, Cohen S, Reid DR, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229

    Article  PubMed  CAS  Google Scholar 

  10. Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16:97–103

    Article  PubMed  CAS  Google Scholar 

  11. Bresssot C, Meunier PJ, Chapuy MC et al (1979) Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Rel Res 1:303–311

    Article  Google Scholar 

  12. Dempster DW (1989) Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4:137–147

    Article  PubMed  CAS  Google Scholar 

  13. Dempster DW, Arlot MA, Meunier PJ (1983) Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 35:410–417

    Article  PubMed  CAS  Google Scholar 

  14. Compston JE, Reginster J-Y, Avouac B et al (1996) Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis. Calcif Tissue Int 59:323–327

    Article  PubMed  CAS  Google Scholar 

  15. Abadie EC, Devogelaer J-P, Ringe JD et al (2005) Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science. Sem Arthritis Rheum 35:1–4

    Article  CAS  Google Scholar 

  16. Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. New Engl J Med 339:292–299

    Article  PubMed  CAS  Google Scholar 

  17. Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42:2309–2318

    Article  PubMed  CAS  Google Scholar 

  18. Reid DM, Hughes RA, Laan RFJM et al (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomised trial. J Bone Miner Res 15:1006–1013

    Article  PubMed  CAS  Google Scholar 

  19. Orwoll ES, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. New Engl J Med 343:604–610

    Article  PubMed  CAS  Google Scholar 

  20. Bobba R, Adachi JD (2007) Review of the safety and efficacy for the treatment of male osteoporosis. Clin Interv Aging 2:275–282

    PubMed  CAS  Google Scholar 

  21. Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

JC has received research grants from Servier and Procter & Gamble and advisory and/or speaking fees from Alliance for Better Bone Health, Amgen, Crescent Diagnostics, Eli Lilly, GlaxoSmith Kline, MSD, Nycomed, Novartis, Pfizer, Procter & Gamble, Roche, Servier and Wyeth. DMR has research grants from Roche, Amgen and Novartis and advisory and/or speaking fees from Amgen, GlaxoSmith Kline, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi-Aventis, Servier and Wyeth. PD has research grants from Procter & Gamble, Eli Lilly and Amgen and advisory and/or speaking fees from Acceleron, Amgen, Eli Lilly, GlaxoSmith Kline, MSD, Novartis, Nycomed, Organon, Pfizer, Procter & Gamble, Roche, Sanofi-Aventis, Servier and Wyeth. JB is an employee of F. Hoffmann-La Roche Ltd. WD is employed by Amgen and is a shareholder in Amgen, Eli Lilly & Co, Merck and Pfizer. J-P D has research grants from Procter & Gamble, Eli Lilly and Novartis and advisory and/or speaking fees from Procter & Gamble, Aventis, Roche, Eli Lilly, Novartis and Servier. LF is an employee of GlaxoSmith Kline. NG is a full time employee of UCB Inc. and owns stock and stock options in UCB Inc. and Procter & Gamble. BM is an employee and shareholder of Eli Lilly & Co. SK is employed by Novartise Pharma AG. JR has received research grants from MSD, Procter & Gamble, Lilly, Servier, Novartis, Nycomed, Roche and GlaxoSmith Kline. RR has received advisory and/or speaking fees from the Alliance for Better Bone Health, Amgen, Danone, Eli Lilly, GlaxoSmith Kline MSD, Nycomed, Novartis, Roche, Servier and Wyeth. J-YR has received research grants from Bristol Myers, MSD, Rottapharm, Teva Lilly, Novartis, Roche, GlaxoSmith Kline, Amgen and Servier and advisory and/or speaking fees from Amgen Analis, Bristol Myers Squibb, Ebewee Pharma, Genevrier, GlaxoSmith~Kline IBSA, Lilly, MSD, Novaris, Nove-Nordisk, NPS, Nycomed, Roche, Rottapharm, Servier, Teijin, Teva, Theramex and Zodiac. MLB, AL, SO, JR, TVS have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK

    J. Compston

  2. University of Aberdeen Medical School, Foresterhill, Aberdeen, AB25 2ZD, UK

    D. M. Reid

  3. Hoffman-La Roche Ltd, Basle, Switzerland

    J. Boisdron

  4. Metabolic Bone Unit, Laboratory of Molecular Genetics, Department of Internal Medicine, University of Florence, Florence, Italy

    M.-L. Brandi

  5. International Osteoporosis Foundation, Nyon, Switzerland

    N. Burlet

  6. Sanofi-Aventis, Cincinnati, USA

    D. Cahall

  7. Department of Medicine, University of Lyon and INSERM Research Unit 831, Lyon, France

    P. D. Delmas

  8. Amgen, Thousand Oaks, CA, USA

    W. Dere

  9. The Arthritis Unit, Université Catholique de Louvain, Brussels, Belgium

    J.-P. Devogelaer

  10. Medicines Disease Center, GlaxoSmithKline, King of Prussia, PA, USA

    L. A. Fitzpatrick

  11. Laboratory of Physiology and Pharmacology, University of Namur, Namur, Belgium

    B. Flamion

  12. Clinical Development, UCB Inc., Smyrna, GA, USA

    N. Goel

  13. Novartis Pharma, AG, Switzerland

    S. Korte

  14. AGES PharmMed, Vienna, Austria

    A. Laslop

  15. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

    B. Mitlak

  16. Icelandic Medicines Control Agency, Seltjarnarnes, Iceland

    S. Ormarsdottir

  17. West German Osteoporosis Center (WOZ) and Med. Clinic 4 at Klinikum Leverkusen, Univerity of Cologne, Cologne, Germany

    J. Ringe

  18. Division of Bone Diseases, WHO Collaborating Centre for Osteoporosis Prevention, Department of Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

    R. Rizzoli

  19. Institut de Recherches Internationales Servier, Courbevoie, France

    Y. Tsouderos

  20. General Practice Research Database, Medicines and Healthcare Products Regulatory Agency, London, UK

    T. Van Staa

  21. Department of Public Health Sciences, University of Liège, Liège, Belgium, Chairman GREES, Liège, Belgium

    J.-Y. Reginster

Authors
  1. J. Compston
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. M. Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Boisdron
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M.-L. Brandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Burlet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D. Cahall
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. D. Delmas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W. Dere
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J.-P. Devogelaer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L. A. Fitzpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B. Flamion
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. N. Goel
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S. Korte
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. A. Laslop
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. B. Mitlak
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S. Ormarsdottir
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. J. Ringe
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. R. Rizzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Y. Tsouderos
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. T. Van Staa
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. J.-Y. Reginster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Compston.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00198-008-0735-7

Rights and permissions

Reprints and permissions

About this article

Cite this article

Compston, J., Reid, D.M., Boisdron, J. et al. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 19, 1247–1250 (2008). https://doi.org/10.1007/s00198-008-0670-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-008-0670-7

Keywords

Search

Navigation